Globe Newswire

ISG Announces Launch of Socrates.AI to Support Next Generation of Claims Management May 16, 2024 06:15AM

DANVERS, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Insight Service Group (ISG), a national provider of claim and litigation support services to the insurance and legal communities, today unveiled Socrates.AI, a groundbreaking platform designed to streamline the process of organizing and summarizing extensive medical reports for professionals in the claims, medical and legal fields.

Socrates.AI stands out for its exceptional ability to extract and analyze vast amounts... (continue reading...)

Alchip Technologies Reports Record Q1 FY2024 Revenue and Net Income May 16, 2024 06:03AM

North America Accounts for 77 Percent of Revenue

Taipei, Taiwan, May 16, 2024 (GLOBE NEWSWIRE) -- Alchip Technologies has reported record revenue of USD$333.6 million for the first quarter of its 2024 fiscal year, topping first quarter FY2023 revenue of USD$188 million by 77.4 percent, and fourth quarter FY2023 revenue of USD$291.1 million by 14.6 percent.

The Company also reported record net income for the first quarter of FY2024 of USD$39 million, up 103.9 percent... (continue reading...)

HSBC Bank Plc - Form 8.5 (EPT/RI) - Wood Group (John) plc May 16, 2024 06:00AM

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the “Code”)

1.         KEY INFORMATION

(a) Name of exempt principal trader:HSBC Bank Plc(b) Name of offeror/offeree in relation to whose relevant securities this form relates:     Use a separate form for each offeror/offereeWood Group (John) plc(c) Name of the party to the offer... (continue reading...)

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) May 16, 2024 06:00AM

– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination with palbociclib were consistent with data previously reported at SABCS in December 2023 –

– At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months (95% CI:... (continue reading...)

South Rampart Pharma Publishes SRP-001's Unique Pain Relief Mechanism and Phase 1 Trial Results in Scientific Reports May 16, 2024 06:00AM

• SRP-001 is a novel, non-opioid new chemical entity without abuse, liver, and kidney toxicities present in current pain medications

• Publication introduces SRP-001 as a safer alternative to existing pain medications

• SRP-001 triggers N-arachidonoylphenolamine (AM404) formation in the midbrain's periaqueductal grey (PAG) region, a potent activator of TRPV1 that plays a crucial role in the brain’s response to pain

• FDA awarded SRP-001 Fast Track designation for acute... (continue reading...)